SPOTLIGHT: Targeted Genetics hits back against trial report
Targeted Genetics went on the attack after The Washington Post raised serious criticisms of a gene therapy trial that was suspended after the death of a volunteer. But Wired also notes that the company's response avoids many of the most serious criticisms leveled in the report. Report
Be the first to comment
More stories about Targeted Genetics
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


